Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date.
Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends this drug has best-in-class potential in a competitive field that includes an Eli Lilly drug that recently posted positive Phase 2 results.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.